Benzinga | Feb 9, 2021 08:00AM EST

Goldman Sachs Reinstates Buy on BridgeBio Pharma, Announces $83 Price Target

Goldman Sachs analyst Paul Choi reinstates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and announces $83 price target.